Literature DB >> 34756880

Human Papillomavirus‒Positive and ‒Negative Vulvar Squamous Cell Carcinoma Are Biologically but Not Clinically Distinct.

Elysha Kolitz1, Elena Lucas2, Gregory A Hosler3, Jiwoong Kim4, Suntrea Hammer5, Cheryl Lewis6, Lin Xu4, Andrew T Day7, Melissa Mauskar8, Jayanthi S Lea9, Richard C Wang10.   

Abstract

Vulvar squamous cell carcinoma pathogenesis is traditionally defined by the presence or absence of human papillomavirus (HPV), but the definition of these groups and their molecular characteristics remain ambiguous across studies. In this study, we present a retrospective cohort analysis of 36 patients with invasive vulvar squamous cell carcinoma where HPV status was determined using RNA in situ hybridization and PCR. Clinical annotation, p16 immunohistochemistry, PD-L1 immunohistochemistry, HPV16 circular E7 RNA detection, and RNA sequencing of the cases were performed. A combination of in situ hybridization and PCR identified 20 cases (55.6%) as HPV positive. HPV status did not impact overall survival (hazard ratio: 1.36, 95% confidence interval = 0.307-6.037, P = 0.6857) or progression-free survival (hazard ratio: 1.12, 95% confidence interval = 0.388-3.22, P = 0.8367), and no significant clinical differences were found between the groups. PD-L1 expression did not correlate with HPV status, but increased expression of PD-L1 correlated with worse overall survival. Transcriptomic analyses (n = 23) revealed distinct groups, defined by HPV status, with multiple differentially expressed genes previously implicated in HPV-induced cancers. HPV-positive tumors showed higher global expression of endogenous circular RNAs, including several circular RNAs that have previously been implicated in the pathogenesis of other cancers.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34756880      PMCID: PMC9038635          DOI: 10.1016/j.jid.2021.10.009

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   7.590


  58 in total

1.  Genomic characterization of vulvar squamous cell carcinoma.

Authors:  Katharina Prieske; Malik Alawi; Leticia Oliveira-Ferrer; Anna Jaeger; Kathrin Eylmann; Eike Burandt; Barbara Schmalfeldt; Simon A Joosse; Linn Woelber
Journal:  Gynecol Oncol       Date:  2020-06-24       Impact factor: 5.482

2.  HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs.

Authors:  Michelle S Longworth; Regina Wilson; Laimonis A Laimins
Journal:  EMBO J       Date:  2005-04-28       Impact factor: 11.598

Review 3.  Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck.

Authors:  Grace C Blitzer; Molly A Smith; Stephen L Harris; Randall J Kimple
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-15       Impact factor: 7.038

4.  Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation.

Authors:  Davis J McCarthy; Yunshun Chen; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2012-01-28       Impact factor: 16.971

5.  HTSeq--a Python framework to work with high-throughput sequencing data.

Authors:  Simon Anders; Paul Theodor Pyl; Wolfgang Huber
Journal:  Bioinformatics       Date:  2014-09-25       Impact factor: 6.937

6.  Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis.

Authors:  Ivano Legnini; Gaia Di Timoteo; Francesca Rossi; Mariangela Morlando; Francesca Briganti; Olga Sthandier; Alessandro Fatica; Tiziana Santini; Adrian Andronache; Mark Wade; Pietro Laneve; Nikolaus Rajewsky; Irene Bozzoni
Journal:  Mol Cell       Date:  2017-03-23       Impact factor: 17.970

7.  CircPCMTD1 Acts as the Sponge of miR-224-5p to Promote Glioma Progression.

Authors:  Si-Qi Zheng; Yue Qi; Jun Wu; Fen-Li Zhou; Hao Yu; Lu Li; Bo Yu; Xiao-Fan Chen; Wei Zhang
Journal:  Front Oncol       Date:  2019-05-22       Impact factor: 6.244

8.  Transforming activity of an oncoprotein-encoding circular RNA from human papillomavirus.

Authors:  Jiawei Zhao; Eunice E Lee; Jiwoong Kim; Rong Yang; Bahir Chamseddin; Chunyang Ni; Elona Gusho; Yang Xie; Cheng-Ming Chiang; Michael Buszczak; Xiaowei Zhan; Laimonis Laimins; Richard C Wang
Journal:  Nat Commun       Date:  2019-05-24       Impact factor: 14.919

9.  Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial.

Authors:  R Wendel Naumann; Antoine Hollebecque; Tim Meyer; Michael-John Devlin; Ana Oaknin; Joseph Kerger; Jose M López-Picazo; Jean-Pascal Machiels; Jean-Pierre Delord; Thomas R J Evans; Valentina Boni; Emiliano Calvo; Suzanne L Topalian; Tian Chen; Ibrahima Soumaoro; Bin Li; Junchen Gu; Ricardo Zwirtes; Kathleen N Moore
Journal:  J Clin Oncol       Date:  2019-09-05       Impact factor: 44.544

10.  The Clinical Relevance of p16 and p53 Status in Patients with Squamous Cell Carcinoma of the Vulva.

Authors:  Ellen L Barlow; Neil Lambie; Mark W Donoghoe; Zin Naing; Neville F Hacker
Journal:  J Oncol       Date:  2020-03-24       Impact factor: 4.375

View more
  3 in total

1.  Assessment of the Abundance and Potential Function of Human Papillomavirus Type 16 Circular E7 RNA.

Authors:  Richard C Wang; Eunice E Lee; Jiawei Zhao; Jiwoong Kim
Journal:  mBio       Date:  2022-05-17       Impact factor: 7.786

2.  High Expression of Circular RNA-Mitochondrial tRNA Translation Optimization 1 Assists the Diagnosis of High-Risk Human Papillomavirus Infection in Cervical Cancer.

Authors:  Xiyun Cheng; Changmei Shen; Zhenrong Liao
Journal:  J Low Genit Tract Dis       Date:  2022-05-14       Impact factor: 3.842

3.  Transcriptome Analysis in Vulvar Squamous Cell Cancer.

Authors:  Katharina Prieske; Malik Alawi; Anna Jaeger; Maximilian Christian Wankner; Kathrin Eylmann; Susanne Reuter; Patrick Lebok; Eike Burandt; Niclas C Blessin; Barbara Schmalfeldt; Leticia Oliveira-Ferrer; Simon A Joosse; Linn Woelber
Journal:  Cancers (Basel)       Date:  2021-12-19       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.